Rx/Reimbursement Adult Incontinence in Lithuania

After the dynamic performance seen in recent years, Rx/reimbursement adult incontinence saw volume and value growth slow considerably in 2024. The steep rise in sales over 2023 stemmed from legislative changes, effectively increasing the monthly allowance of adult incontinence products provided under prescription. With consumers able to access more products under prescription, retail sales plummeted in 2023, with the government effectively subsidising more sales via Rx.

Euromonitor International's Rx/Reimbursement adult incontinence in Lithuania report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2020-2024, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they new product developments, distribution or pricing issues. Forecasts to 2029 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Rx/Reimbursement adult incontinence market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.